Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2012

Nov 28, 2012

30016_dirs_2012-11-28_fd2a25a9-bcdc-41fd-bfdc-9e1b07caf0cf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2012-11-27

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-11-27 Common Stock M 20000 $17.1350 Acquired 393133 Direct
2012-11-27 Common Stock S 13000 $92.4966 Disposed 380133 Direct
2012-11-27 Common Stock S 2000 $93.8064 Disposed 378133 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-11-27 Non-Qualified Stock Option (right to buy) $17.135 M 20000 Disposed 2013-02-06 Common Stock (20000) Direct

Footnotes

F1: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/27/2012.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $92.26 to $93.18, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $93.47 to $94.06, inclusive.

F4: Grant of options to buy shares of common stock becomes exercisable as to 30,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, and 02/06/2007, and the remaining 24,164 shares on 02/06/2008.